Widely invasive follicular thyroid carcinoma (FTC) is a pathologically distinct and clinically more aggressive subtype of follicular thyroid cancer. Patients in this category carry a significantly poorer prognosis than those with minimally invasive FTC, raising distinct management considerations.
This protocol addresses follicular thyroid cancer presenting as widely invasive follicular thyroid carcinoma — a higher-risk pathological subtype associated with increased risk of distant and local metastasis compared to minimally invasive disease.
Management in this setting includes a systemic radionuclide-based therapy as a key component of the treatment pathway, directed at addressing residual disease and enabling surveillance for metastatic spread.
The complete structured regimen — including sequencing, additional interventions, and follow-up strategy — is available via the full protocol.
Since the prognosis of patients with widely invasive FTC is significantly poorer compared to patients with minimally invasive FTC, completion total thyroidectomy with radioactive iodine (RAI) therapy for widely invasive FTC to detect the appearance of distant and local metastasis is strongly recommended in clinical practice guidelines.
Recurrence and distant metastasis of FTC are treated with RAI.
DOI: 10.1530/ETJ-24-0146
View source ↗